-
T-DXd Reevaluated in HER2-Low/HER2-Negative Breast Cancer After New Trials
05 Feb 2025 05:27 GMT
… HER2 immunohistochemistry (IHC) 0 breast cancer.
Received lumpectomy and sentinel … by 5 years of letrozole.
Eight months after … HR-positive, HER2-negative breast cancer?
Laura Huppert, MD: … -negative breast cancer, as well as triple-negative breast cancer with …
-
The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment
31 Jan 2025 18:18 GMT
… . For endocrine-susceptible breast cancers, the next line … metastatic breast cancer. Presented at: San Antonio Breast Cancer Symposium; … metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022; … and letrozole co-pack for early high-risk breast cancer. …
-
Roche announces positive results from phase III INAVO120 study of Itovebi in combo with palbociclib & fulvestrant in a certain type of HR─positive advanced breast cancer
29 Jan 2025 05:39 GMT
… locally advanced or metastatic breast cancer whose disease progressed … #47;6i and letrozole versus placebo plus a … -negative breast cancer (INAVO123; NCT06790693).
HR-positive breast cancer is … the most prevalent type of all breast cancers, …
-
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancer
29 Jan 2025 01:37 GMT
… 2 negative (HER2) negative breast cancers.
This news comes three … positive, HER2-negative, advanced breast cancer.
Primary analysis from the … HR-positive, PIK3CA-mutated breast cancer live longer.”
The INAVO120 … CDK4/6i and letrozole.
Now, the company has …
-
Hydroxychloroquine Enhances the Efficacy of Palbociclib, Letrozole Therapy in Patients With HR+, HER2– Metastatic Breast Cancer
28 Jan 2025 22:54 GMT
… Pfizer) and standard letrozole (Femara; Novartis Pharmaceuticals Corporation) … (HER2−) metastatic breast cancer (MBC), according … letrozole efficacy in ER+/HER2− breast cancer. npj Breast Cancer … positive, HER2 negative breast cancer. Updated April 19 …
-
Novartis taps Hailee Steinfeld, Wanda Sykes for breast cancer Super Bowl ad
28 Jan 2025 22:52 GMT
… Komen, Living Beyond Breast Cancer, TOUCH (The Black Breast Cancer Alliance) and Breastcancer. … ribociclib) and Kisqali Femara Co-Pack for treating early breast cancer.
“We are … healthcare providers, and the wider breast cancer community,” said Victor Bultó, …
-
Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer
28 Jan 2025 17:16 GMT
… PIK3CA-mutated breast cancer live longer,” … -negative breast cancer following progression … letrozole in endocrine-sensitive, PIK3CA-mutated hormone receptor–positive, HER2-negative breast cancer … .
Additional studies of inavolisib in breast cancer …
-
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
28 Jan 2025 06:16 GMT
… 47;6i and letrozole versus placebo plus … breast cancer
HR-positive breast cancer is the most prevalent type of all breast cancers … in Breast Cancer
Genentech has been advancing breast cancer research … breast cancers. As our understanding of breast cancer …
-
Risk of Subclinical Hypothyroidism in Breast Cancer Patients Treated With CT-Guided Radiation Therapy: A Prospective Observational Study
25 Jan 2025 15:12 GMT
… breast cancer. The risk was particularly elevated in breast cancer … (Tamoxifen or Letrozole), malignancy grade … breast cancer-a Danish matched cohort study. Breast Cancer … breast cancer: national guidelines and contouring atlas by the Danish breast cancer …
-
Endocrine-Immune-Based Therapies Improved Responses in Chemo-Insensitive Patients With HR+/HER2– Breast Cancer
24 Jan 2025 18:47 GMT
… 2-negative (HER2–) breast cancer (BC), with outcomes … Jiangsu Hengrui Medicine Co], letrozole [Femara; Novartis Pharmaceuticals Corporation] … clinical trial of breast cancer neo-adjuvant therapy … HR+/HER2- breast cancer-FINEST study. Cancer Communications …
About
© 1995-2025